BioXcel Therapeutics (NASDAQ:BTAI) Raised to Hold at Wall Street Zen

BioXcel Therapeutics (NASDAQ:BTAI) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other analysts have also weighed in on BTAI. Weiss Ratings reiterated a “sell (e+)” rating on shares of BioXcel Therapeutics in a research note on Wednesday, January 21st. Rodman & Renshaw initiated coverage on shares of BioXcel Therapeutics in a research report on Tuesday, March 17th. They set a “buy” rating and a $17.00 target price for the company. HC Wainwright lowered their price target on shares of BioXcel Therapeutics from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Thursday, March 5th. Finally, Zacks Research raised BioXcel Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, March 9th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, BioXcel Therapeutics has an average rating of “Hold” and a consensus target price of $11.50.

BioXcel Therapeutics Trading Down 8.0%

BTAI opened at $1.26 on Friday. BioXcel Therapeutics has a 12-month low of $1.17 and a 12-month high of $8.08. The firm has a 50 day moving average of $1.60 and a two-hundred day moving average of $1.99. The firm has a market capitalization of $27.56 million, a PE ratio of -0.13 and a beta of 0.18.

Institutional Trading of BioXcel Therapeutics

Institutional investors have recently bought and sold shares of the business. Oaktree Capital Management LP purchased a new stake in shares of BioXcel Therapeutics in the second quarter valued at approximately $437,000. SLT Holdings LLC purchased a new position in shares of BioXcel Therapeutics during the 3rd quarter valued at approximately $76,000. Foundations Investment Advisors LLC purchased a new position in shares of BioXcel Therapeutics during the 3rd quarter valued at approximately $76,000. Jones Financial Companies Lllp grew its stake in BioXcel Therapeutics by 38.5% in the 3rd quarter. Jones Financial Companies Lllp now owns 36,000 shares of the company’s stock valued at $97,000 after acquiring an additional 10,000 shares during the period. Finally, Man Group plc purchased a new stake in BioXcel Therapeutics in the 4th quarter worth $91,000. 30.68% of the stock is owned by institutional investors and hedge funds.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.